Lidocaine lore: from WWII Stockholm tests to dentistry and smart fragrances

Summary

In this Chemistry World piece, the lidocaine story unfolds from a dramatic WWII-era Stockholm test to its status as a widely used local anesthetic in dentistry. The podcast also introduces a contemporary fragrance topic, hinting at smart release strategies using cyclodextrins. Across these segments, listeners learn about the chemistry behind lidocaine, its mechanism of action on neuronal ion channels, and the historical and business context that shaped its use. A lighter note closes with a tease of next week’s compound spotlight.

• Lidocaine’s WWII origins and its rise in dentistry
• Mechanism as a sodium-channel blocker and water stability via amide linkage
• Stockholm era researchers, patent history, and Astra’s evolution
• Fragrance science and cyclodextrins as a future scent technology

Introduction

The podcast covers two main stories that sit at the intersection of chemistry and its real-world impact. The first is lidocaine, a local anesthetic with a remarkable provenance linked to Stockholm during the mid-20th century. The second concerns the fragrance industry and the prospect of smart fragrances that release scent in response to activity, powered in part by cyclodextrins. Both threads illuminate how chemistry translates into medical practice and consumer products.

Lidocaine: from Stockholm to dentistry

The lidocaine narrative begins with a vivid wartime tableau in which two young scientists at Stockholm University tested an anesthetic preparation labeled LL30. One scientist, Wengt Lundqvist, injected himself with a solution of white crystals prepared by Inge Fischer, while his colleague Nils Loewgen oversaw the experiment. The scene, described on a 1963 television program, illustrates the ad hoc nature of early anesthetic research. LL30 is now known as lidocaine, a substance whose safety and efficacy would eventually make it a mainstay of local anesthesia. The tests reportedly caused dangerous drops in pulse, only to be revived with adrenaline, a routine the researchers described matter-of-factly. Lidocaine’s rise was helped by its water stability compared with earlier anesthetics; this stability is due to its amide bond, in contrast to Novocaine’s ester linkage, which required frequent preparation. The molecule targets neuronal ion channels and blocks sodium transport, interrupting pain signaling. Lidocaine’s dental use became ubiquitous, helping to numb mouths during procedures, while its antiarrhythmic properties earned it a place in heart medicine as well.

The personal and professional arcs surrounding lidocaine are also part of the story. Lundqvist died in 1953 in an accident, while Loewgen left Stockholm University in 1964 amid disillusionment with administrative burdens and the broader Swedish university system. Inga Fischer, the chemist who first synthesized the molecule, later became a prominent theoretical physicist at Stockholm University and died in 2008 after the AstraZeneca lidocaine business had shifted through the pharmaceutical landscape. The right to lidocaine was sold to Astra, a small Swedish company that grew into a pharmaceutical heavyweight and later merged with Seneca in the 1990s. The patent, tied to the original synthesis and its derivatives, eventually expired, contributing to the drug’s widespread generics market.

Chemistry and pharmacology of lidocaine

Lidocaine is described as a synthetic drug that nonetheless sits within a class of anesthetics closely modeled on cocaine. The compound is not naturally occurring, but it sits within a lineage headed by cocaine-like structures. Its stability in water is attributed to an amide bond, which keeps lidocaine more soluble than ester-containing predecessors like Novocaine, which required water-based fresh preparation. Lidocaine works by blocking ion channels in neuronal membranes, inhibiting sodium ion transport, and thereby dampening pain signal transmission. Beyond dentistry, lidocaine has had a role in treating ventricular arrhythmias and other medical indications, with a curious historical note about its use by Pope Pius XII for hiccups, whose rationale remains unclear. The story also touches on medical business history, including Astra’s growth and eventual sale of most lidocaine operations, reflecting how pharmaceutical portfolios evolve over decades.

Smart fragrances and cyclodextrins

The second segment explores fragrance longevity as a consumer value. A fragrance scientist explains how customers expect scents to persist and release in a controlled manner across the day. The concept of smart fragrances aims to enhance scent delivery in response to activity, with cyclodextrins highlighted as a potential mechanism for controlled, on-demand fragrance release. The discussion hints at a future where fragrance is more responsive to physical exertion, integrating chemistry with scented experiences in everyday products.

Closing

The host Teases next week’s compound spotlight, inviting listeners to return for another element of Chemistry in Its Element hosted by Chemistry World and produced by the Naked Scientists.